FTC and DOJ Target Healthcare and Life Sciences Industries

FTC and DOJ Target Healthcare and Life Sciences Industries

Client Alert

Related Documents

Related Solutions

We offer clients exceptional insight in dealing with competition agencies in the United States, Europe and around the world.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Guiding clients through high-stakes and sensitive investigations.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

The healthcare industry remains a focal point of President Biden’s antitrust agenda. The President’s July 2021 Executive Order on Promoting Competition in the American Economy called on federal agencies to focus antitrust enforcement efforts on health care, among other industries, and to coordinate on oversight, investigations, and remedies where agency jurisdiction overlaps. The Federal Trade Commission (FTC), the Department of Justice Antitrust Division (DOJ), and the Department of Health and Human Services (HHS) later announced plans to address antitrust concerns in the healthcare industry. FTC Chair Lina M. Khan highlighted ongoing healthcare-related enforcement initiatives in a February 2024 speech before the American Medical Association. The FTC, DOJ, and HHS launched an interagency inquiry into private equity and corporate ownership in health care shortly thereafter. In this client alert, we summarize the latest federal antitrust activities in the healthcare industry.

Read the full alert.

Authors

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel